Fibroblast Growth Factor 2 Implicated in Childhood Anxiety and Depression Symptoms

Overview

Journal J Affect Disord

Date 2021 Jan 14

PMID 33445083

Citations 5

Authors

Eli R Lebowitz

Meital Orbach

Carla E Marin

Natalina Salmaso

Flora M Vaccarino

Wendy K Silverman

Affiliations

Soon will be listed here.

Abstract

Background: Research links fibroblast growth factor 2 (FGF2) to anxiety and depression in rodents and human adults. Our study is the first to examine FGF2 levels in a pediatric population.

Methods: We assayed serum FGF2 in 163 children with a broad range of anxiety and depressive symptoms; 111 were clinic-referred anxious and depressed children; 52 were non-referred children. We examined associations between FGF2 and anxiety and depression symptoms, and between each of the three facets of behavioral activation (Reward-Responsiveness, Drive, Fun-Seeking) and behavioral avoidance. We used confirmatory factor analysis (CFA) to determine the relative contribution of anxiety and depression indicators and of FGF2 to a latent variable of Anxiety/Depression. We also examined stability of FGF2 levels.

Results: FGF2 levels in clinic-referred children were significantly lower compared with non-referred children. Bivariate correlations and CFA showed negative associations between FGF2 and anxiety, depression and behavioral avoidance. FGF2 levels were positively correlated with the Reward-Responsiveness facet of behavioral activation, implicated in depression. FGF2 levels were stable over six months.

Limitations: We did not have data on behavioral avoidance and stability of FGF2 in the entire sample.

Conclusions: Our results implicate FGF2 in anxiety and depression in children, providing an important first step in showing FGF2 may serve as a stable biomarker for these prevalent and impairing problems.

Citing Articles

Regulation of Hair Follicle Growth and Development by Different Alternative Spliceosomes of FGF5 in Rabbits.

Sun S, Zhao B, Li J, Zhang X, Yao S, Bao Z Genes (Basel). 2024; 15(4).

PMID: 38674344 PMC: 11049220. DOI: 10.3390/genes15040409.

The relationship between salivary Fibroblast Growth Factor-2 and cortisol reactivity and psychological outcomes prior to and during the COVID-19 pandemic.

Bryant E, Richardson R, Graham B J Affect Disord Rep. 2023; 13:100606.

PMID: 37304226 PMC: 10246939. DOI: 10.1016/j.jadr.2023.100606.

Network pharmacology and experimental studies for deciphering the molecular targets and mechanisms of Chaihu Shugan powder in the treatment of functional dyspepsia.

Wang Y, Wang X, Jiang K, Yang K, Ling J Technol Health Care. 2023; 31(S1):449-462.

PMID: 37038797 PMC: 10200242. DOI: 10.3233/THC-236039.

The Association Between Salivary FGF2 and Physiological and Psychological Components of the Human Stress Response.

Bryant E, Richardson R, Graham B Chronic Stress (Thousand Oaks). 2022; 6:24705470221114787.

PMID: 35874911 PMC: 9297468. DOI: 10.1177/24705470221114787.

New developments in the biology of fibroblast growth factors.

Ornitz D, Itoh N WIREs Mech Dis. 2022; 14(4):e1549.

PMID: 35142107 PMC: 10115509. DOI: 10.1002/wsbm.1549.

References

Graham B, Zagic D, Richardson R . Low Endogenous Fibroblast Growth Factor 2 Levels Are Associated With Heightened Conditioned Fear Expression in Rats and Humans. Biol Psychiatry. 2017; 82(8):601-607. DOI: 10.1016/j.biopsych.2017.03.020. View

Cummings C, Caporino N, Kendall P . Comorbidity of anxiety and depression in children and adolescents: 20 years after. Psychol Bull. 2013; 140(3):816-45. PMC: 4006306. DOI: 10.1037/a0034733. View

Vaccarino F, Schwartz M, Raballo R, Nilsen J, Rhee J, Zhou M . Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci. 1999; 2(3):246-53. DOI: 10.1038/6350. View

He S, Zhang T, Hong B, Peng D, Su H, Lin Z . Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neurosci Lett. 2014; 579:168-72. DOI: 10.1016/j.neulet.2014.07.035. View

Lebowitz E, Shic F, Campbell D, MacLeod J, Silverman W . Avoidance moderates the association between mothers' and children's fears: findings from a novel motion-tracking behavioral assessment. Depress Anxiety. 2014; 32(2):91-8. DOI: 10.1002/da.22333. View

Beesdo-Baum K, Jenjahn E, Hofler M, Lueken U, Becker E, Hoyer J . Avoidance, safety behavior, and reassurance seeking in generalized anxiety disorder. Depress Anxiety. 2012; 29(11):948-57. DOI: 10.1002/da.21955. View

Bredy T, Grant R, Champagne D, Meaney M . Maternal care influences neuronal survival in the hippocampus of the rat. Eur J Neurosci. 2003; 18(10):2903-9. DOI: 10.1111/j.1460-9568.2003.02965.x. View

Silverman W, Pina A, Viswesvaran C . Evidence-based psychosocial treatments for phobic and anxiety disorders in children and adolescents. J Clin Child Adolesc Psychol. 2008; 37(1):105-30. DOI: 10.1080/15374410701817907. View

Evans S, Choudary P, Neal C, Li J, Vawter M, Tomita H . Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A. 2004; 101(43):15506-11. PMC: 523463. DOI: 10.1073/pnas.0406788101. View

10.

Kiraly D, Horn S, Van Dam N, Costi S, Schwartz J, Kim-Schulze S . Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry. 2017; 7(3):e1065. PMC: 5416674. DOI: 10.1038/tp.2017.31. View

11.

Salmaso N, Stevens H, McNeill J, Elsayed M, Ren Q, Maragnoli M . Fibroblast Growth Factor 2 Modulates Hypothalamic Pituitary Axis Activity and Anxiety Behavior Through Glucocorticoid Receptors. Biol Psychiatry. 2016; 80(6):479-489. PMC: 8009045. DOI: 10.1016/j.biopsych.2016.02.026. View

12.

Lebowitz E, Francois B . Using Motion Tracking to Measure Avoidance in Children and Adults: Psychometric Properties, Associations With Clinical Characteristics, and Treatment-Related Change. Behav Ther. 2018; 49(6):853-865. PMC: 6394864. DOI: 10.1016/j.beth.2018.04.005. View

13.

Turner C, Calvo N, Frost D, Akil H, Watson S . The fibroblast growth factor system is downregulated following social defeat. Neurosci Lett. 2007; 430(2):147-50. PMC: 2241657. DOI: 10.1016/j.neulet.2007.10.041. View

14.

Deng Z, Deng S, Zhang M, Tang M . Fibroblast Growth Factors in Depression. Front Pharmacol. 2019; 10:60. PMC: 6370647. DOI: 10.3389/fphar.2019.00060. View

15.

Simard S, Shail P, MacGregor J, El Sayed M, Duman R, Vaccarino F . Fibroblast growth factor 2 is necessary for the antidepressant effects of fluoxetine. PLoS One. 2018; 13(10):e0204980. PMC: 6166983. DOI: 10.1371/journal.pone.0204980. View

16.

Turner C, Watson S, Akil H . The fibroblast growth factor family: neuromodulation of affective behavior. Neuron. 2012; 76(1):160-74. PMC: 3476848. DOI: 10.1016/j.neuron.2012.08.037. View

17.

Perez J, Clinton S, Turner C, Watson S, Akil H . A new role for FGF2 as an endogenous inhibitor of anxiety. J Neurosci. 2009; 29(19):6379-87. PMC: 2748795. DOI: 10.1523/JNEUROSCI.4829-08.2009. View

18.

Kahl K, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L . Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology. 2008; 34(3):353-7. DOI: 10.1016/j.psyneuen.2008.09.016. View

19.

Galvez-Contreras A, Campos-Ordonez T, Lopez-Virgen V, Gomez-Plascencia J, Ramos-Zuniga R, Gonzalez-Perez O . Growth factors as clinical biomarkers of prognosis and diagnosis in psychiatric disorders. Cytokine Growth Factor Rev. 2016; 32:85-96. DOI: 10.1016/j.cytogfr.2016.08.004. View

20.

Depue R, Iacono W . Neurobehavioral aspects of affective disorders. Annu Rev Psychol. 1989; 40:457-92. DOI: 10.1146/annurev.ps.40.020189.002325. View